Sharifi R, Ojeda L, Lee M
Urol Int. 1987;42(1):62-6. doi: 10.1159/000281853.
In an open, prospective clinical trial, we evaluated the safety and efficacy of apalcillin in the treatment of complicated urinary tract infection. 21 hospitalized adult patients received apalcillin 2 g IV Q8-12 h for 5-17 days. There were 8 upper tract and 13 lower tract infections. Of 25 functional or anatomic abnormalities of the GU tract among these patients, 9 (36%) were corrected during the study period. Effectiveness of apalcillin was determined by clinical and bacteriologic response. 16 (76.2%) patients had clinical cures, 4 (19.8%) had clinical improvement, and 1 (4.8%) had clinical failure. Based on 26 pretreatment isolates, there were 16 (61.5%) bacteriologic cures and 10 (38.5%) failures. Failures were due to 6 (23.1%) relapses, 2 (7.7%) superinfections, and 2 (7.7%) relapses with superinfection. Adverse reactions were mild, transient, and did not require discontinuation of treatment. Apalcillin appears to be a safe, although marginally effective single agent antibiotic for the treatment of complicated urinary tract infections.
在一项开放性前瞻性临床试验中，我们评估了阿帕西林治疗复杂性尿路感染的安全性和有效性。21例住院成年患者接受阿帕西林静脉注射2 g，每8 - 12小时一次，共治疗5 - 17天。其中上尿路感染8例，下尿路感染13例。在这些患者的25例泌尿系统功能或解剖异常中，9例（36%）在研究期间得到纠正。阿帕西林的有效性通过临床和细菌学反应来确定。16例（76.2%）患者临床治愈，4例（19.8%）临床改善，1例（4.8%）临床失败。基于26株治疗前分离菌株，有16例（61.5%）细菌学治愈，10例（38.5%）失败。失败原因包括6例（23.1%）复发、2例（7.7%）二重感染以及2例（7.7%）复发合并二重感染。不良反应轻微且短暂，无需停药。阿帕西林似乎是一种安全的单一药物抗生素，尽管对治疗复杂性尿路感染的效果略显有限。
